Your shopping cart is currently empty

STL001 is a potent and selective inhibitor of FOXM1. It triggers the translocation of nuclear FOXM1 to the cytoplasm, promoting autophagic degradation. STL001 enhances the sensitivity of human cancers to broad-spectrum cancer therapies.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | STL001 is a potent and selective inhibitor of FOXM1. It triggers the translocation of nuclear FOXM1 to the cytoplasm, promoting autophagic degradation. STL001 enhances the sensitivity of human cancers to broad-spectrum cancer therapies. |
| In vitro | STL001, in concentrations ranging from 1-10 μM over 24 hours, causes a dose-dependent reduction in cellular FOXM1 protein levels. At 5 μM for 24 hours, STL001 prompts the translocation of nuclear FOXM1 to the cytoplasm, enhancing its autophagic degradation. In U2OS-C3-luc cells, treatment with 5 μM for 24 hours resulted in decreased FOXM1 levels and elevated expression of the autophagy marker protein LC3. |
| Molecular Weight | 509.52 |
| Formula | C27H23N7O4 |
| Cas No. | 3047493-70-6 |
| Smiles | O=C(OC1=CC=CC(=C1)C2=NN(C=C2)C3=NC(=NC(=N3)N4CCOCC4)NC=5C=CC=CC5)C=6OC=CC6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.